ATE278777T1 - Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität - Google Patents
Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivitätInfo
- Publication number
- ATE278777T1 ATE278777T1 AT94916597T AT94916597T ATE278777T1 AT E278777 T1 ATE278777 T1 AT E278777T1 AT 94916597 T AT94916597 T AT 94916597T AT 94916597 T AT94916597 T AT 94916597T AT E278777 T1 ATE278777 T1 AT E278777T1
- Authority
- AT
- Austria
- Prior art keywords
- kgf
- keratinocyte growth
- shortened
- growth factor
- biological activity
- Prior art date
Links
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title abstract 3
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 title abstract 2
- 230000004071 biological effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000057239 human FGF7 Human genes 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8642793A | 1993-06-29 | 1993-06-29 | |
| PCT/US1994/004694 WO1995001434A1 (en) | 1993-06-29 | 1994-04-28 | A truncated keratinocyte growth factor (kgf) having increased biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE278777T1 true ATE278777T1 (de) | 2004-10-15 |
Family
ID=22198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94916597T ATE278777T1 (de) | 1993-06-29 | 1994-04-28 | Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US5677278A (de) |
| EP (2) | EP0706563B1 (de) |
| JP (4) | JP3570516B2 (de) |
| KR (1) | KR960703433A (de) |
| CN (1) | CN1129955A (de) |
| AT (1) | ATE278777T1 (de) |
| AU (1) | AU681405B2 (de) |
| BG (1) | BG100236A (de) |
| BR (1) | BR9407035A (de) |
| CA (1) | CA2166278A1 (de) |
| CZ (1) | CZ343795A3 (de) |
| DE (2) | DE122006000005I2 (de) |
| DK (1) | DK0706563T3 (de) |
| ES (1) | ES2227527T3 (de) |
| FI (1) | FI956203A (de) |
| FR (1) | FR06C0004I2 (de) |
| HU (1) | HUT73453A (de) |
| LU (1) | LU91215I2 (de) |
| NL (1) | NL300217I2 (de) |
| NO (1) | NO955189D0 (de) |
| NZ (1) | NZ266622A (de) |
| PL (1) | PL312257A1 (de) |
| PT (1) | PT706563E (de) |
| SK (1) | SK153295A3 (de) |
| WO (1) | WO1995001434A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20022681B (en) * | 1989-01-31 | 2002-04-25 | Aaronson Us Stuart A | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth |
| US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| US5814605A (en) * | 1993-03-26 | 1998-09-29 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| US7084119B2 (en) * | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| NZ266622A (en) | 1993-06-29 | 1997-10-24 | Chiron Corp | Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates |
| EP1334981B1 (de) * | 1994-10-13 | 2011-01-26 | Swedish Orphan Biovitrum AB (publ) | Methode zur Reinigung von Keratinozyten-Wachstumfaktoren |
| WO1996011949A2 (en) * | 1994-10-13 | 1996-04-25 | Amgen Inc. | Analogs of keratinocyte growth factor |
| AU745815B2 (en) * | 1994-10-13 | 2002-04-11 | Biovitrum Ab (Publ) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using |
| US6008328A (en) * | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| ATE274056T1 (de) | 1995-10-11 | 2004-09-15 | Chiron Corp | Kombination pdgf, kgf, igf und igfbp zur wundheilung |
| US6692961B1 (en) | 1996-10-11 | 2004-02-17 | Invitrogen Corporation | Defined systems for epithelial cell culture and use thereof |
| US20030144202A1 (en) * | 1996-10-15 | 2003-07-31 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
| EP1473366A1 (de) * | 1996-10-15 | 2004-11-03 | Amgen Inc. | Produkte des Keratinocyten-Wachstumsfaktors 2 |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| JP2001506975A (ja) * | 1996-10-15 | 2001-05-29 | アムジェン インコーポレイテッド | ケラチノサイト増殖因子―２産物 |
| AU7970498A (en) * | 1997-06-19 | 1999-01-04 | Genetics Institute Inc. | Secreted proteins and polynucleotides encoding them |
| US20080233086A1 (en) * | 1997-09-05 | 2008-09-25 | Canbiocin Inc. | Expression Vectors for Treating Bacterial Infections |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| US6238888B1 (en) | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| AU762519B2 (en) * | 1998-02-13 | 2003-06-26 | Human Genome Sciences, Inc. | Therapeutic uses of keratinocyte growth factor-2 |
| DE19934510B4 (de) * | 1999-07-22 | 2009-04-16 | Vermicon Ag | Verfahren zum Nachweis von Mikroorganismen |
| US6485937B1 (en) | 1999-10-15 | 2002-11-26 | The Rockefeller University | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
| DE10024334B4 (de) * | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| US6812221B2 (en) | 2000-11-21 | 2004-11-02 | The Texas A&M University System | FGF-affinity chromatography |
| EP1357931A2 (de) * | 2001-01-08 | 2003-11-05 | Human Genome Sciences, Inc. | Keratinozyt-wachstumsfaktor-2 |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| CA2457781A1 (en) * | 2001-08-21 | 2003-02-27 | Chiron Corporation | Kgf polypeptide compositions |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| NZ555503A (en) * | 2004-12-15 | 2010-01-29 | Biovitrum Ab Publ | Therapeutic formulations of keratinocyte growth factor |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| EP1969001A2 (de) * | 2005-11-22 | 2008-09-17 | Novartis Vaccines and Diagnostics, Inc. | Norovirus- und sapovirus-antigene |
| GB0611405D0 (en) * | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US20080119433A1 (en) * | 2006-07-06 | 2008-05-22 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
| KR101021197B1 (ko) * | 2008-04-11 | 2011-03-11 | (주)케어젠 | 성장인자―미미킹 펩타이드 및 그의 용도 |
| CN102471769A (zh) | 2009-07-17 | 2012-05-23 | 亚伦·T.·塔波尔 | 用于具有美容功能的细胞的遗传修饰以提高美容外观的方法和组合物 |
| RU2016117275A (ru) | 2013-11-01 | 2017-12-04 | Сфериум Биомед С.Л. | Тельца включения для трансдермальной доставки терапевтических и косметических средств |
| AU2022336409A1 (en) | 2021-08-30 | 2024-02-15 | Unichem Laboratories Limited | Protein compositions for the treatment of inflammatory diseases |
| KR102691028B1 (ko) * | 2021-11-15 | 2024-08-05 | (주)피앤피바이오팜 | 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20022681B (en) | 1989-01-31 | 2002-04-25 | Aaronson Us Stuart A | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5814605A (en) | 1993-03-26 | 1998-09-29 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
| NZ266622A (en) | 1993-06-29 | 1997-10-24 | Chiron Corp | Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates |
| JP4422210B2 (ja) | 1994-10-13 | 2010-02-24 | アムジエン・インコーポレーテツド | ケラチノサイト増殖因子アナログ |
| WO1996011949A2 (en) | 1994-10-13 | 1996-04-25 | Amgen Inc. | Analogs of keratinocyte growth factor |
-
1994
- 1994-04-28 NZ NZ266622A patent/NZ266622A/en unknown
- 1994-04-28 WO PCT/US1994/004694 patent/WO1995001434A1/en active IP Right Grant
- 1994-04-28 EP EP94916597A patent/EP0706563B1/de not_active Expired - Lifetime
- 1994-04-28 ES ES94916597T patent/ES2227527T3/es not_active Expired - Lifetime
- 1994-04-28 AU AU68208/94A patent/AU681405B2/en not_active Ceased
- 1994-04-28 BR BR9407035A patent/BR9407035A/pt not_active Application Discontinuation
- 1994-04-28 CA CA002166278A patent/CA2166278A1/en not_active Abandoned
- 1994-04-28 SK SK1532-95A patent/SK153295A3/sk unknown
- 1994-04-28 JP JP50346495A patent/JP3570516B2/ja not_active Expired - Fee Related
- 1994-04-28 AT AT94916597T patent/ATE278777T1/de active
- 1994-04-28 PT PT94916597T patent/PT706563E/pt unknown
- 1994-04-28 KR KR1019950705997A patent/KR960703433A/ko not_active Application Discontinuation
- 1994-04-28 DK DK94916597T patent/DK0706563T3/da active
- 1994-04-28 EP EP04023638A patent/EP1493812A3/de not_active Ceased
- 1994-04-28 CZ CZ953437A patent/CZ343795A3/cs unknown
- 1994-04-28 HU HU9503857A patent/HUT73453A/hu unknown
- 1994-04-28 CN CN94193193A patent/CN1129955A/zh active Pending
- 1994-04-28 DE DE1994634053 patent/DE122006000005I2/de active Active
- 1994-04-28 DE DE69434053T patent/DE69434053T2/de not_active Expired - Lifetime
- 1994-04-28 PL PL94312257A patent/PL312257A1/xx unknown
-
1995
- 1995-03-27 US US08/410,941 patent/US5677278A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,937 patent/US5863767A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,547 patent/US5843883A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,546 patent/US5773586A/en not_active Expired - Lifetime
- 1995-12-20 NO NO955189A patent/NO955189D0/no unknown
- 1995-12-20 BG BG100236A patent/BG100236A/xx unknown
- 1995-12-22 FI FI956203A patent/FI956203A/fi unknown
-
1998
- 1998-05-08 US US09/074,950 patent/US6074848A/en not_active Expired - Lifetime
-
2000
- 2000-05-16 US US09/573,068 patent/US6677301B1/en not_active Expired - Fee Related
-
2004
- 2004-02-10 JP JP2004034289A patent/JP2004166709A/ja not_active Withdrawn
-
2005
- 2005-11-17 JP JP2005333438A patent/JP2006075173A/ja not_active Withdrawn
-
2006
- 2006-01-26 NL NL300217C patent/NL300217I2/nl unknown
- 2006-01-27 LU LU91215C patent/LU91215I2/en unknown
- 2006-01-31 FR FR06C0004C patent/FR06C0004I2/fr active Active
-
2007
- 2007-06-11 US US11/811,560 patent/US20090093400A1/en not_active Abandoned
-
2008
- 2008-11-26 JP JP2008301630A patent/JP4662569B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE278777T1 (de) | Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität | |
| ATE354659T1 (de) | Polypeptide mit kinaseaktivität, ihre herstellung und verwendung | |
| PT839196E (pt) | Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8 | |
| DE69024862D1 (de) | Modifiziertes, biologisch aktives Protein | |
| DK0759067T3 (da) | Transformerende vækstfaktor alfa-H1 | |
| ATE139569T1 (de) | Modifizierter, menschlicher gewebeplasminogenaktivator und seine herstellung | |
| DE69126049D1 (de) | Vektoren und Zusammensetzungen zur Expression von Glykosilationsmutanten des menschlichen Proteins-C | |
| ATE166359T1 (de) | Peptide mit einer lanthionin-brücke | |
| AU3095892A (en) | Human type antibody reactive with GPIIb/IIIa | |
| DE59409964D1 (de) | Rekombinante D-Hydantoinase, Verfahren zur Herstellung und Verwendung | |
| ATE145939T1 (de) | Mitogen für die glatte muskulatur und dessen kodierende dns | |
| IT1231764B (it) | Composizione poliuretanica con capacita' di assorbire umidita', particolarmente adatta per la fabbricazione di cuoio sintetico e simili, e procedimento per la sua produzione. | |
| JPS6480298A (en) | Production of human proapolipoprotein a-i-like protein | |
| EP0206329A3 (en) | Sprung floor | |
| ES2137610T3 (es) | Somier. | |
| AU4315396A (en) | Monoclonal antibody | |
| DK51893D0 (da) | 1,2,3-thiadiazol-4-thio-forbindelser | |
| IT219518Z2 (it) | Leva di comando particolarmente per l'azionamento di gruppi valvolari |